NCT03012477View on ClinicalTrials.gov

CISPLATIN + AZD-1775 In Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 18, 2017

Primary Completion Date

May 7, 2019

Study Completion Date

November 30, 2020

Conditions
Triple-negative Metastatic Breast Cancer
Interventions
DRUG

Cisplatin

chemotherapy

DRUG

AZD1775

Wee1 tyrosine kinase inhibitor

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER